Editor Profile

Andrey Anisimov

University/Organization: University of Helsinki

Country: Finland

 Biography

Dr. Andrey Anisimov was graduated from the Petrozavodsk State University, Petrozavodsk, Russia. He obtained his PhD in cellular and molecular biology at St.-Petersburg State University in 1995. During his PhD studies he investigated the effects of chemical inducers of differentiation of cancer cells on their sensitivity to the cells of innate immunity, such as native and activated natural killer cells. After few years work at the private biotechnological company in Helsinki, Finland, Dr. Anisimov has moved to academic field and currently holds positions of Adj. Professor and a Senior scientist at the Translational cancer Biology Program, University of Helsinki and Wihuri Research Institute and a Research manager of the AAV Gene Transfer and Cell Therapy Core Facility (HelVí – Helsinki Virus Core) in the University of Helsinki. As a Research manager at the Core Facility Dr. Anisimov supervises design and production of recombinant viral vectors for research applications. The Core provides international-wide service. His research work is mainly focused on angiogenesis and lymphangiogenesis in healthy and pathological tissues and regulation of endothelial cell responses to various stimuli associated with inflammation, cancer growth and developmental cues. He was a recipient of several research grants and awards, including Medix prize in 2011 for the best Finnish scientific paper in molecular biology. He was a member of AHA/ASA (American Heart/Stroke Association) and European Society of Gene and Cell Therapy (ESGCT).